Recent advances in genotyping and sequencing technologies are turning liquid biopsies into a clinically viable alternative to tissue biopsies, the current gold standard for making treatment decisions.
As research validates the ability of liquid biopsies to screen asymptomatic patients, detect cancer, measure tumor burden, predict recurrence, monitor disease progression and evaluate response to treatment, the quest for developing clinically actionable liquid biopsy tests has just started.
The rapid drop in cost of analyzing genetic information combined with the increase in use of targeted cancer therapeutics are opening windows of opportunities for start-ups with the right technologies.
Many innovative start-ups are exploring liquid biopsy's potential for providing oncologists with a faster, cheaper and less invasive way to assess colorectal, lung, prostate, breast and ovarian cancer patients' clinical status and response to treatment.
Combining liquid biopsies with personalized therapies has the potential to revolutionize cancer care and the market opportunity is attracting attention from a wide range of companies into this rapidly evolving field and accelerating the pace of acquisitions in the space.
Targeted at senior executives in the medical diagnostics industry, Medtech Ventures’ “Emerging Liquid Biopsy Market” report explores emerging business models, revenue potential and successful growth strategies in this rapidly evolving field.
The report sizes the current liquid biopsy market, profiles key players and offers a rational overview of this emerging sector with a sober forecast to 2020.